Predictors of Clinical and Immunological Failure Among Patients on First-Line Antiretroviral Therapy (ART) in Southwest Ethiopia

References

• GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019;6(12):e831–e859.
   Google Scholar
• WHO. Antiretroviral therapy (ART) coverage among all age groups [Internet]. WHO. 2017 [cited 27, 2017]. Available from: http://www.who.int/gho/hiv/epidemic_response/ART/en/. Accessed 1219, 2019.
   Google Scholar
• WHO. Global Health Observatory (GHO) data: numberof deaths due to HIV/AIDS [Internet]. WHO. 2017 [cited 27, 2017]. Available from: http://www.who.int/gho/hiv/epidemic_status/deaths_text/en/. Accessed 1219, 2019.
   Google Scholar
• UNAIDS. How AIDS changed every thing: howworked to achieve the Millennium development goals [Internet]. 2013 Available from: http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf. Accessed 1219, 2019.
   Google Scholar
• Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. JAIDS J Acquir Immune Defic Syndr. 2012;61(2):158–163. doi:10.1097/QAI.0b013e3182615ad122692090
   PubMed Web of Science ®Google Scholar
• Ramadhani HO, Bartlett JA, Thielman NM, et al. Association of first-line and second-line antiretroviral therapy adherence. Open Forum Infect Dis. 2014;1(2):ofu079–ofu079. doi:10.1093/ofid/ofu07925734147
   PubMedGoogle Scholar
• Boyd MA. Current and future management of treatment failure in low- and middle-income countries. Curr Opin HIV AIDS. 2010;5(1):83–89. doi:10.1097/COH.0b013e328333b8c020046152
   PubMed Web of Science ®Google Scholar
• Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23(6):697–700. doi:10.1097/QAD.0b013e3283262a7819209067
   PubMed Web of Science ®Google Scholar
• Rawizza HE, Chaplin B, Meloni ST, et al. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Clin Infect Dis. 2011;53(12):1283–1290. doi:10.1093/cid/cir72922080121
   PubMed Web of Science ®Google Scholar
• MPONDO, Bonaventura CT, et al. Prevalence and predictors of immunological failure among HIV-infected adults on HAART in Northwestern Tanzania: a cross sectional study. Tanzan Med J. 2016;27(1):55–69.
   Google Scholar
• Ginwalla R, Chama E, Kawamya-Banda F, Thomas R, Mwiya M, Kankasa C. Prevalence of clinical, immunological and irological failure among children on Haart at the university teaching hospital, Lusaka, Zambia. Med J Zambia. 2012;39(3):1–5.
   Google Scholar
• Teshome Yimer Y, Yalew AW. Magnitude and predictors of Anti-Retroviral Treatment (ART) failure in private health facilities in Addis Ababa, Ethiopia. PLoS One. 2015;10(5):e0126026. doi:10.1371/journal.pone.012602625946065
   PubMed Web of Science ®Google Scholar
• Haile D, Takele A, Gashaw K, Demelash H, Nigatu D. Predictors of treatment failure among Adult Antiretroviral Treatment (ART) clients in bale zone hospitals, South Eastern Ethiopia. PLoS One. 2016;11(10):e0164299. doi:10.1371/journal.pone.016429927716827
   PubMed Web of Science ®Google Scholar
• Bayou B, Sisay A, Kumie A. Assessment of the magnitude and associated factors of immunological failure among adult and adolescent HIV-infected patients in St. Luke and Tulubolo Hospital, Oromia Region, Ethiopia. Pan Afr Med J. 2015;21. doi:10.11604/pamj.2015.21.291.6831
   Google Scholar
• Yirdaw KD, Hattingh S. Prevalence and predictors of immunological failure among HIV patients on HAART in Southern Ethiopia. Paraskevis D, editor. PLoS One. 2015;10(5):e0125826. doi:10.1371/journal.pone.012582625961732
   PubMed Web of Science ®Google Scholar
• Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatmentregimen where therapeutic options are limited. Int Med Press. 2007;12(1):83–88.
   Google Scholar
• Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MAW, Calmy A, AIDS Working Group of MSF. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304(3):303–312. doi:10.1001/jama.2010.98020639564
   PubMed Web of Science ®Google Scholar
• UNAIDS. Worrying rates of second-line HIV treatment failure [Internet]. JOHANNESBURG; 2010 [cited 27, 2017]. Available from: http://www.irinnews.org/news/2010/08/04/worrying-rates-second-line-hiv-treatment-failure.
   Google Scholar
• Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health. 2010;15(2):251–258. doi:10.1111/tmi.2010.15.issue-220003034
   PubMed Web of Science ®Google Scholar
• Desmonde S, Eboua F, Malateste K, et al. Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation. AIDS. 2015;29(12):1527–1536. doi:10.1097/QAD.000000000000070726244392
   PubMed Web of Science ®Google Scholar
• Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis. 2012;12(1):197. doi:10.1186/1471-2334-12-19722916836
   PubMed Web of Science ®Google Scholar
• Alemu Melsew Y. Rate of immunological failure and its predictors among patients on highly active antiretroviral therapy at Debremarkos Hospital, Northwest Ethiopia: a retrospective follow up study. J AIDS Clin Res. 2013;04(05). doi:10.4172/2155-6113
   Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. [Internet]. 2013 [cited 27, 2017]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK195400/.
   Google Scholar
• Mitra S, Gogolishvili D. Rapid response service. rapid response: disclosure of HIV-positive status [Internet]. Ontario HIV Treatment Network; 2013 Available from: http://publichealth.lacounty.gov/dhsp/Contractors/MCC/RapidResponseDisclosure.pdf.Accessed 1219, 2019.
   Google Scholar
• Vanobberghen FM, Kilama B, Wringe A, et al. Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. Trop Med Int Health. 2015;20(7):880–892. doi:10.1111/tmi.1250725779383
   PubMed Web of Science ®Google Scholar
• Muzah BP, Takuva S, Maskew M, Delany-Moretlwe S. Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study. Afr J HIV Med. 2012;13(4):168–172. doi:10.4102/sajhivmed.v13i4.110
   Google Scholar
• Nyesigire Ruhinda E, Bajunirwe F, Kiwanuka J. Anaemia in HIV-infected children: severity, types and effect on response to HAART. BMC Pediatr. 2012;12(1). doi:10.1186/1471-2431-12-170
   Web of Science ®Google Scholar
• Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin Infect Dis. 2004;38(10):1454–1463. doi:10.1086/38303115156485
   PubMed Web of Science ®Google Scholar
• Lumbiganon P, Kosalaraksa P, Bunupuradah T, et al. HIV-infected children in the Asia-Pacific region with baseline severe anemia: antiretroviral therapy and outcomes. Asian Biomed. 2016;10(3):229–234.
   Web of Science ®Google Scholar